Online citations, reference lists, and bibliographies.

Pomalidomide Plus Low-dose Dexamethasone Versus High-dose Dexamethasone Alone For Patients With Relapsed And Refractory Multiple Myeloma (MM-003): A Randomised, Open-label, Phase 3 Trial.

Jesús F. San Miguel, Katja Christina Weisel, Philippe Moreau, Martha Q Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrián Macías Alegre, Christine I. Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquín Martínez-López, Andrew Belch, Antonio Palumbo, Stephen A. Schey, P. Sonneveld, Xin Yu, Lars Sternas, Christian Jacques, Mohamed Zaki, Meletios Athanasios Dimopoulos
Published 2013 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have been noted when combined with dexamethasone. We compared the efficacy and safety of pomalidomide plus low-dose dexamethasone with high-dose dexamethasone alone in these patients. METHODS This multicentre, open-label, randomised phase 3 trial was undertaken in Australia, Canada, Europe, Russia, and the USA. Patients were eligible if they had been diagnosed with refractory or relapsed and refractory multiple myeloma, and had failed at least two previous treatments of bortezomib and lenalidomide. They were assigned in a 2:1 ratio with a validated interactive voice and internet response system to either 28 day cycles of pomalidomide (4 mg/day on days 1-21, orally) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally) or high-dose dexamethasone (40 mg/day on days 1-4, 9-12, and 17-20, orally) until disease progression or unacceptable toxicity. Stratification factors were age (≤75 years vs >75 years), disease population (refractory vs relapsed and refractory vs bortezomib intolerant), and number of previous treatments (two vs more than two). The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01311687, and with EudraCT, number 2010-019820-30. FINDINGS The accrual for the study has been completed and the analyses are presented. 302 patients were randomly assigned to receive pomalidomide plus low-dose dexamethasone and 153 high-dose dexamethasone. After a median follow-up of 10·0 months (IQR 7·2-13·2), median PFS with pomalidomide plus low-dose dexamethasone was 4·0 months (95% CI 3·6-4·7) versus 1·9 months (1·9-2·2) with high-dose dexamethasone (hazard ratio 0·48 [95% CI 0·39-0·60]; p<0·0001). The most common grade 3-4 haematological adverse events in the pomalidomide plus low-dose dexamethasone and high-dose dexamethasone groups were neutropenia (143 [48%] of 300 vs 24 [16%] of 150, respectively), anaemia (99 [33%] vs 55 [37%], respectively), and thrombocytopenia (67 [22%] vs 39 [26%], respectively). Grade 3-4 non-haematological adverse events in the pomalidomide plus low-dose dexamethasone and high-dose dexamethasone groups included pneumonia (38 [13%] vs 12 [8%], respectively), bone pain (21 [7%] vs seven [5%], respectively), and fatigue (16 [5%] vs nine [6%], respectively). There were 11 (4%) treatment-related adverse events leading to death in the pomalidomide plus low-dose dexamethasone group and seven (5%) in the high-dose dexamethasone group. INTERPRETATION Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients with refractory or relapsed and refractory multiple myeloma. FUNDING Celgene Corporation.
This paper references
A phase 2 study of single-agent carfi
DS Siegel (2013)
A phase 1/2 study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma
JR Berenson (2012)
10.1182/BLOOD.V120.21.2979.2979
A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
James R. Berenson (2012)
10.1046/j.1365-2141.1998.00930.x
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
Joan Bladé (1998)
Quality of life improvements for pomalidomide + low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma Haematologica
J San Miguel (2013)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib therapy: a multicentre International Myeloma
SK Kumar (2012)
10.1200/JCO.2004.10.052
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Steve A. Schey (2004)
10.1182/blood-2012-09-452375
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Xavier Leleu (2013)
10.1038/leu.2009.236
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Hang Quach (2010)
10.1182/BLOOD.V120.21.201.201
Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients
Martha Q Lacy (2012)
10.1182/BLOOD.V120.21.1852.1852
PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma
Paul G Richardson (2012)
Quality of life improvements for pomalidomide + low - dose dexamethasone ( POM + LoDEX ) in relapsed and refractory multiple myeloma
KC Weisel
10.1056/NEJMOA070596
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Donna M. Weber (2007)
10.1182/blood.v118.21.480.480
Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial
David S Siegel (2011)
Quality of life improvements for pomalidomide + low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma
J San Miguel (2013)
10.1182/BLOOD.V120.21.4062.4062
Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort
Rachid Baz (2012)
10.1056/NEJMoa030288
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G Richardson (2003)
10.1182/blood-2012-05-425934
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
David S Siegel (2012)
10.1182/blood-2012-08-450742
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Paul G Richardson (2013)
10.1038/sj.leu.2405016
Clinically relevant end points and new drug approvals for myeloma
Kenneth C. Anderson (2008)
A phase 2 study of single - agent carfi lzomib ( PX - 171 - 003 - A 1 ) in patients with relapsed and refractory multiple myeloma
DS Siegel (2012)
10.1056/NEJMOA070594
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Meletios Athanasios Dimopoulos (2007)
10.1056/NEJMoa043445
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Paul G Richardson (2005)
10.1038/LEU.2012.15
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Shaji K Kumar (2012)
10.1182/BLOOD.V120.21.4036.4036
A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma
Ashraf Z Badros (2012)
10.1182/BLOOD.V120.21.74.74
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
Jatin J. Shah (2012)
10.1182/BLOOD.V120.21.446.446
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma
Antonio Palumbo (2012)
10.1182/BLOOD.V120.21.450.450
Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis
Sundar Jagannath (2012)
10.1200/JCO.2011.29.15_SUPPL.TPS225
A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
Philippe Moreau (2011)
10.1111/j.1365-2141.2008.07013.x
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Matthew J Streetly (2008)
10.1182/BLOOD.V120.21.21.21
Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up
Sam Schulman (2012)
10.1182/blood.v118.21.134.134
Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM
Enrique M Ocio (2011)
lzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM)
AZ Badros (2011)
10.1038/sj.leu.2404284
International uniform response criteria for multiple myeloma
B G M Durie (2006)
10.1038/leu.2011.196
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Shaji K Kumar (2012)
10.1182/BLOOD.V120.21.727.727
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Paul G Richardson (2012)



This paper is referenced by
10.1182/blood-2016-02-700872
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
Meletios Athanasios Dimopoulos (2016)
10.1182/blood-2017-05-785246
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Ajai Chari (2017)
10.1111/cas.13550
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Shinsuke Iida (2018)
10.1016/S1470-2045(15)00412-X
Influencing cancer treatment.
Esther Holgado (2015)
10.6004/jadpro.2017.8.1.7
Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
Joseph A. Kalis (2017)
Target Expression , Genera tion , Preclinical Activity , and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM 801 for Multiple Myeloma Treatment Graphical
Anja Seckinger ()
1 High-Risk Multiple Myeloma : Integrated Clinical 2 and Omics Approach Dissects the Neoplastic Clone 3 and the Tumor Microenvironment 4
Antonio Giovanni Solimando (2019)
10.1038/s41408-019-0245-1
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
Cinnie Yentia Soekojo (2019)
10.1093/jjco/hyz083
Immunomodulatory drugs in the treatment of multiple myeloma.
Yu Abe (2019)
10.1182/BLOOD-2016-05-717769
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Shaji K Kumar (2016)
10.1097/MD.0000000000002305
Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
Pei Hsu (2015)
10.1080/2162402X.2016.1254856
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
Tomas Jelinek (2016)
How I Treat How I treat relapsed myeloma
Joan Bladé (2015)
10.2147/DDDT.S115456
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
R Ríos-Tamayo (2017)
10.3389/fimmu.2018.02431
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Tomas Jelinek (2018)
10.3892/mco.2018.1775
Tolerability and safety of real-world use of pomalidomide in patients with relapsed/refractory multiple myeloma.
Eiseki Usami (2019)
10.1002/ajh.25791
Multiple Myeloma: 2020 update on Diagnosis, Risk-stratification and Management.
Sundararajan Vincent Rajkumar (2020)
10.1016/j.ejmech.2019.111906
Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.
Reeder M. Robinson (2019)
10.1111/cas.14139
Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
Shinsuke Iida (2019)
10.1002/hon.2205
Improved survival of older patients with multiple myeloma in the era of novel agents.
Ulrich J M Mey (2016)
10.1111/bjh.14213
Multiple myeloma: patient outcomes in real‐world practice
Kwee L Yong (2016)
10.1111/bjh.13100
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Donna E. Reece (2015)
10.1016/j.ceb.2015.10.004
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Andrew A Guirguis (2015)
10.1111/joim.12590
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.
Ola Landgren (2017)
10.1055/s-0034-1370793
Venous thromboembolism in multiple myeloma.
Valerio De Stefano (2014)
10.1182/blood-2016-07-729236
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
I S Nijhof (2016)
The cost-effectiveness of pomalidomide for treating patients with relapsed multiple myeloma refractory to both lenalidomide and bortezomib
Vera ten Holder (2014)
10.1517/14656566.2015.1075507
An update in treatment options for multiple myeloma in nontransplant eligible patients
Annemiek Broijl (2015)
10.1007/978-3-319-18218-6_5
Treatment of relapsed multiple myeloma
Michel Delforge (2015)
10.1016/j.soncn.2017.05.005
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Kimberly Noonan (2017)
10.1007/978-3-319-25586-6_5
Treatment of Relapsed/Refractory Patients with Multiple Myeloma
Jacob P Laubach (2018)
10.1038/s41375-018-0024-1
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
S Bringhen (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar